- Abiomed Announces Q1 FY 2019 Record Revenue of $180 Million, Up 36% Over Prior Year
- Abiomed Announces Q4 FY 2018 Revenue of $174 Million, Up 40%, and Total Year Revenue of $594 Million, Up 33%, Over Prior Year
- Abiomed Announces European Approval (CE Marking) for Impella 5.5(TM) and First Patient Treated at University Heart Center Hamburg
- Abiomed to Appoint New Chief Financial Officer Todd A. Trapp
Abiomed Inc (ABMD:NSQ) closed at 362.06, -21.25% below its 52-week high of 459.75, set on Oct 01, 2018.
258.10Mar 01 2018459.75Oct 01 2018
Markit short selling activity
|Market cap||16.32bn USD|
|EPS (TTM)||4.79 |
Data delayed at least 15 minutes, as of Feb 15 2019 21:00 GMT.